Crossmark

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

Crossref DOI link: https://doi.org/10.1186/s12933-019-0964-4

Published Online: 2019-11-28

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shao, Qingmiao

Meng, Lei

Lee, Sharen

Tse, Gary

Gong, Mengqi

Zhang, Zhiwei

Zhao, Jichao

Zhao, Yungang

Li, Guangping

Liu, Tong http://orcid.org/0000-0003-0482-0738
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81570298, 81970270)

Natural Science Foundation of Tianjin City (16JCZDJC34900)
License Information

Text and Data Mining valid from 2019-11-28

Version of Record valid from 2019-11-28
More Information

Article History

Received: 12 June 2019

Accepted: 10 November 2019

First Online: 28 November 2019

Ethics approval and consent to participate

: The study was approved by the Experimental Animal Administration Committee of Tianjin Medical University and Tianjin Municipal Commission for Experimental Animal Control.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below